A multi-scale approach to designing therapeutics for tuberculosis

Integrative Biology (United Kingdom)

Volumn 7, Issue 5, 2015, Pages 591-609

  Linderman, Jennifer J ^a   Cilfone, Nicholas A ^a   Pienaar, Elsje ^a,b   Gong, Chang ^a   Kirschner, Denise E ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR; VACCINE; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; IL10 PROTEIN, HUMAN;

ANTIBIOTIC THERAPY; ARTICLE; COMPUTER SIMULATION; GRANULOMA; IMMUNE RESPONSE; IMMUNOMODULATION; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SYSTEMS BIOLOGY; TUBERCULOSIS; ANIMAL; BIOLOGY; COMPUTER LANGUAGE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECTS; HUMAN; IMMUNE SYSTEM; INHALATIONAL DRUG ADMINISTRATION; MACROPHAGE; METABOLISM; ORAL DRUG ADMINISTRATION;

MYCOBACTERIUM TUBERCULOSIS;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BIOMARKERS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GRANULOMA; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-10; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; PROGRAMMING LANGUAGES; SYSTEMS BIOLOGY; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929153556     PISSN: 17579694     EISSN: 17579708     Source Type: Journal    
DOI: 10.1039/c4ib00295d     Document Type: Article

References (132)

1. WHO, Global tuberculosis report, 2014
2. V. Dartois The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells Nat. Rev. Microbiol. 2014 12 3 159 167
3. L. Ramakrishnan Revisiting the role of the granuloma in tuberculosis. Nature reviews Immunology 2012 12 5 352 366
4. J. L. Flynn J. Chan Immunology of tuberculosis Annu. Rev. Immunol. 2001 19 93 129
5. A. O'Garra et al., The immune response in tuberculosis Annu. Rev. Immunol. 2013 31 475 527
6. J. L. Flynn Lessons from experimental Mycobacterium tuberculosis infections Microbes Infect. 2006 8 4 1179 1188
7. J. L. Flynn and E. Klein, Pulmonary Tuberculosis in Monkeys, in A Color Atlas of Comparative Pulmonary Tuberculosis Histopathology, ed., V. D. J. Leong, and, T. Dick, CRC Press, Taylor & Francis, 2011, pp. 83-106
8. P. L. Lin J. L. Flynn Understanding latent tuberculosis: a moving target J. Immunol. 2010 185 1 15 22
9. R. L. Modlin B. R. Bloom TB or not TB: that is no longer the question Sci. Transl. Med. 2013 5 213 213sr6
10. P. L. Lin et al., Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing Nat. Med. 2014 20 1 75 79
11. P. L. Lin et al., Early events in Mycobacterium tuberculosis infection in cynomolgus macaques Infect. Immun. 2006 74 7 3790 3803
12. P. L. Lin et al., Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model Infect. Immun. 2009 77 10 4631 4642
13. H. P. Gideon J. L. Flynn Latent tuberculosis: what the host "sees"? Immunol. Res. 2011 50 2-3 202 212
14. N. A. Cilfone et al., Multi-scale modeling predicts a balance of tumor necrosis factor-alpha and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection PLoS One 2013 8 7 e68680
15. S. Marino et al., TNF and IL-10 are major factors in modulation of the phagocytic cell environment in lung and lymph node in tuberculosis: a next-generation two-compartmental model J. Theor. Biol. 2010 265 4 586 598
16. J. E. Wigginton D. Kirschner A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis J. Immunol. 2001 166 3 1951 1967
17. P. L. Lin et al., Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens Antimicrob. Agents Chemother. 2013 57 9 4237 4244
18. G. Guzzetta D. Kirschner The roles of immune memory and aging in protective immunity and endogenous reactivation of tuberculosis PLoS One 2013 8 4 e60425
19. C. E. Barry, 3rd et al., The spectrum of latent tuberculosis: rethinking the biology and intervention strategies Nat. Rev. Microbiol. 2009 7 12 845 855
20. M. Fallahi-Sichani et al., Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability J. Immunol. 2012 188 7 3169 3178
21. S. Marino et al., Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue PLoS Comput. Biol. 2007 3 10 1909 1924
22. S. D. Chakravarty et al., Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs Infect. Immun. 2008 76 3 916 926
23. J. Harris J. C. Hope J. Keane Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis J. Infect. Dis. 2008 198 12 1842 1850
24. R. S. Wallis et al., Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin. Infect. Dis. 2004 38 9 1261 1265
25. H. M. Blumberg et al., American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med. 2003 167 4 603 662
26. Y. Zhang W. W. Yew M. R. Barer Targeting persisters for tuberculosis control Antimicrob. Agents Chemother. 2012 56 5 2223 2230
27. J. E. Gomez J. D. McKinney M. tuberculosis persistence, latency, and drug tolerance Tuberculosis 2004 84 1-2 29 44
28. Z. Ahmad et al., The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters J. Antimicrob. Chemother. 2010 65 10 2172 2175
29. L. E. Connolly P. H. Edelstein L. Ramakrishnan Why is long-term therapy required to cure tuberculosis? PLoS Med. 2007 4 3 e120
30. D. A. Mitchison How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis Int. J. Tuberc. Lung Dis. 1998 2 1 10 15
31. S. E. Weis et al., The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis N. Engl. J. Med. 1994 330 17 1179 1184
32. K. C. Chang et al., Treatment of tuberculosis and optimal dosing schedules Thorax 2011 66 11 997 1007
33. C. Saltini Schedule or dosage? The need to perfect intermittent regimens for tuberculosis Am. J. Respir. Crit. Care Med. 2006 174 10 1067 1068
34. A. Zumla P. Nahid S. T. Cole Advances in the development of new tuberculosis drugs and treatment regimens Nat. Rev. Drug Discovery 2013 12 5 388 404
35. M. Fallahi-Sichani et al., Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma PLoS Comput. Biol. 2010 6 5 e1000778
36. S. Tay et al., Single-cell NF-kappaB dynamics reveal digital activation and analogue information processing Nature 2010 466 7303 267 271
37. D. A. Braun M. Fribourg S. C. Sealfon Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation J. Biol. Chem. 2013 288 5 2986 2993
38. E. Giacomini et al., Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response J. Immunol. 2001 166 12 7033 7041
39. R. Blomgran et al., Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells Cell Host Microbe 2012 11 1 81 90
40. V. E. Watson et al., Apoptosis in mycobacterium tuberculosis infection in mice exhibiting varied immunopathology J. Pathol. 2000 190 2 211 220
41. H. Qin et al., SOCS3 deficiency promotes M1 macrophage polarization and inflammation J. Immunol. 2012 189 7 3439 3448
42. S. P. Cavnar et al., Microfluidic source-sink model reveals effects of biophysically distinct CXCL12 isoforms in breast cancer chemotaxis Integr. Biol. 2014 6 5 564 576
43. J. T. Mattila et al., Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms J. Immunol. 2013 191 2 773 784
44. J. J. Linderman D. E. Kirschner In silico models of M. tuberculosis infection provide a route to new therapies Drug Discovery Today: Dis. Models 2014
45. J. M. Davis L. Ramakrishnan The role of the granuloma in expansion and dissemination of early tuberculous infection Cell 2009 136 1 37 49
46. L. E. Via et al., Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates Infect. Immun. 2008 76 6 2333 2340
47. M. Fallahi-Sichani, et al., A systems biology approach for understanding granuloma formation and function in tuberculosis, in Systems biology of tuberculosis, ed., D. Beste, A. Kierzek, and, J. McFadden, Springer, 2013
48. M. Fallahi-Sichani et al., Multiscale computational modeling reveals a critical role for TNF-alpha receptor 1 dynamics in tuberculosis granuloma formation J. Immunol. 2011 186 6 3472 3483
49. M. Fallahi-Sichani D. E. Kirschner J. J. Linderman NF-kappaB Signaling Dynamics Play a Key Role in Infection Control in Tuberculosis Front. Physiol. 2012 3 170
50. J. C. Ray J. L. Flynn D. E. Kirschner Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection J. Immunol. 2009 182 6 3706 3717
51. J. L. Segovia-Juarez S. Ganguli D. Kirschner Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model J. Theor. Biol. 2004 231 3 357 376
52. N. A. Cilfone et al., Computational modeling predicts interleukin-10 control of lesion sterilization by balancing early host-immunity-mediated antimicrobial responses with caseation during mycobacterium tuberculosis infection J. Immunol. 2015 194 2 664 677
53. S. Marino et al., Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection Infect. Immun. 2014 83 1 324 338
54. N. A. Cilfone D. E. Kirschner J. J. Linderman Strategies for efficient numerical implementation of hybrid multi-scale agent-based models to describe biological systems Cell. Mol. Bioeng. 2014 8 1 119 136
55. D. E. Kirschner et al., Tuneable resolution as a systems biology approach for multi-scale, multi-compartment computational models Wiley Interdiscip. Rev.: Syst. Biol. Med. 2014 6 4 289 309
56. S. Marino J. J. Linderman D. E. Kirschner A multifaceted approach to modeling the immune response in tuberculosis Wiley Interdiscip. Rev.: Syst. Biol. Med. 2011 3 4 479 489
57. S. Marino et al., A methodology for performing global uncertainty and sensitivity analysis in systems biology J. Theor. Biol. 2008 254 1 178 196
58. E. Pienaar et al., A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment J. Theor. Biol. 2015 367 166 179
59. P. L. Lin et al., Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques Proc. Natl. Acad. Sci. U. S. A. 2012 109 35 14188 14193
60. M. C. Kjellsson et al., Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions Antimicrob. Agents Chemother. 2012 56 1 446 457
61. J. J. Wilkins et al., Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients Br. J. Clin. Pharmacol. 2011 72 1 51 62
62. J. J. Wilkins et al., Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption Antimicrob. Agents Chemother. 2008 52 6 2138 2148
63. F. B. Pruijn et al., Prediction of Tumour Tissue Diffusion Coefficients of Hypoxia-Activated Prodrugs from Physicochemical Parameters Aust. J. Chem. 2008 61 9 687 693
64. P. M. Jeena et al., In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis Antimicrob. Agents Chemother. 2011 55 2 539 545
65. N. Mor et al., Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages Antimicrob. Agents Chemother. 1995 39 9 2073 2077
66. A. Forsgren A. Bellahsene Antibiotic accumulation in human polymorphonuclear leucocytes and lymphocytes Scand. J. Infect. Dis., Suppl. 1985 44 16 23
67. H. M. Ziglam et al., Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy J. Antimicrob. Chemother. 2002 50 6 1011 1015
68. M. M. Schmidt K. D. Wittrup A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther. 2009 8 10 2861 2871
69. J. E. de Steenwinkel et al., Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis J. Antimicrob. Chemother. 2010 65 12 2582 2589
70. R. Jayaram et al., Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis Antimicrob. Agents Chemother. 2003 47 7 2118 2124
71. R. Jayaram et al., Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis Antimicrob. Agents Chemother. 2004 48 8 2951 2957
72. T. Gumbo et al., Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations Antimicrob. Agents Chemother. 2007 51 7 2329 2336
73. N. A. Cilfone et al., Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis CPT: Pharmacometrics Syst. Pharmacol. 2015 4 e22
74. S. Marino M. El-Kebir D. Kirschner A hybrid multi-compartment model of granuloma formation and T cell priming in Tuberculosis J. Theor. Biol. 2011 280 1 50 62
75. C. Gong J. J. Linderman D. E. Kirschner Harnessing the heterogeneity of T cell differentiation fate to fine-tune generation of effector and memory T cells Front. Immunol. 2014 5 57 10.3389/fimmu.2014.00057
76. J. L. Flynn et al., An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection J. Exp. Med. 1993 178 6 2249 2254
77. P. L. Lin et al., Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model Arthritis Rheuma 2010 62 2 340 350
78. W. Ouyang et al., Regulation and functions of the IL-10 family of cytokines in inflammation and disease Annu. Rev. Immunol. 2011 29 71 109
79. K. W. Moore et al., Interleukin-10 and the interleukin-10 receptor Annu. Rev. Immunol. 2001 19 683 765
80. C. Bogdan Y. Vodovotz C. Nathan Macrophage deactivation by interleukin 10 J. Exp. Med. 1991 174 6 1549 1555
81. M. K. Balcewicz-Sablinska H. Gan H. G. Remold Interleukin 10 produced by macrophages inoculated with Mycobacterium avium attenuates mycobacteria-induced apoptosis by reduction of TNF-alpha activity J. Infect. Dis. 1999 180 4 1230 1237
82. D. M. Higgins et al., Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection Tuberculosis 2009 89 2 149 157
83. P. S. Redford P. J. Murray A. O'Garra The role of IL-10 in immune regulation during M. tuberculosis infection Mucosal Immunol. 2011 4 3 261 270
84. R. M. Savic et al., Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies J. Pharmacokinet. Pharmacodyn. 2007 34 5 711 726
85. R. R. Regoes et al., Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens Antimicrob. Agents Chemother. 2004 48 10 3670 3676
86. R. Loddenkemper D. Sagebiel A. Brendel Strategies against multidrug-resistant tuberculosis Eur. Respir. J. Suppl. 2002 36 66s 77s
87. P. Ankomah B. R. Levin Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections Proc. Natl. Acad. Sci. U. S. A. 2014 111 23 8331 8338
88. A. Sosnik et al., New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery Adv. Drug Delivery Rev. 2010 62 4-5 547 559
89. P. Muttil C. Wang A. J. Hickey Inhaled drug delivery for tuberculosis therapy Pharm. Res. 2009 26 11 2401 2416
90. A. Misra et al., Inhaled drug therapy for treatment of tuberculosis Tuberculosis 2011 91 1 71 81
91. G. Griffiths et al., Nanobead-based interventions for the treatment and prevention of tuberculosis Nat. Rev. Microbiol. 2010 8 11 827 834
92. J. Siepmann F. Siepmann Mathematical modeling of drug delivery Int. J. Pharm. 2008 364 2 328 343
93. D. G. Kanjickal S. T. Lopina Modeling of drug release from polymeric delivery systems-a review Crit. Rev. Ther. Drug Carrier Syst. 2004 21 5 345 386
94. D. Y. Arifin L. Y. Lee C. H. Wang Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems Adv. Drug Delivery Rev. 2006 58 12-13 1274 1325
95. W. J. Burman K. Gallicano C. Peloquin Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials Clin. Pharmacokinet. 2001 40 5 327 341
96. P. L. Lin et al., The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection J. Clin. Invest. 2012 122 1 303 314
97. J. Weiner, 3rd S. H. Kaufmann Recent advances towards tuberculosis control: vaccines and biomarkers J. Intern. Med. 2014 275 5 467 480
98. C. Montagnani et al., Vaccine against tuberculosis: what's new? BMC Infect. Dis. 2014 14 suppl 1 S2
99. S. H. Kaufmann Tuberculosis vaccines: time to think about the next generation Semin. Immunol. 2013 25 2 172 181
100. C. Aagaard et al., A multistage tuberculosis vaccine that confers efficient protection before and after exposure Nat. Med. 2011 17 2 189 194
101. P. Andersen J. S. Woodworth Tuberculosis vaccines-rethinking the current paradigm Trends Immunol. 2014 35 8 387 395
102. C. Gong et al., Predicting lymph node output efficiency using systems biology J. Theor. Biol. 2013 335C 169 184
103. J. J. Linderman et al., Characterizing the dynamics of CD4+ T cell priming within a lymph node J. Immunol. 2010 184 6 2873 2885
104. J. P. Girard T. A. Springer High endothelial venules (HEVs): specialized endothelium for lymphocyte migration Immunol. Today 1995 16 9 449 457
105. L. R. Shiow et al., CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs Nature 2006 440 7083 540 544
106. C. P. Bhunu et al., Modelling the effects of pre-exposure and post-exposure vaccines in tuberculosis control J. Theor. Biol. 2008 254 3 633 649
107. N. Jamshidi B. O. Palsson Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets BMC Syst. Biol. 2007 1 26
108. R. A. Slayden et al., Updating and curating metabolic pathways of TB Tuberculosis 2013 93 1 47 59
109. D. J. Beste et al., (1)(3)C metabolic flux analysis identifies an unusual route for pyruvate dissimilation in mycobacteria which requires isocitrate lyase and carbon dioxide fixation PLoS Pathog. 2011 7 7 e1002091
110. J. E. Galagan et al., The Mycobacterium tuberculosis regulatory network and hypoxia Nature 2013 499 7457 178 183
111. K. S. Rao, D. Kumar and S. Mande, Probing Gene Regulatory Networks to Decipher Host-Pathogen Interactions, in Systems biology of tuberculosis, ed., J. McFadden, D. Beste, and, A. M. Kierzek, Springer, 2013
112. D. J. Beste et al., (13)C-Flux Spectral Analysis of Host-Pathogen Metabolism Reveals a Mixed Diet for Intracellular Mycobacterium tuberculosis Chem. Biol. 2013 20 8 1012 1021
113. A. Sambarey K. Prashanthi N. Chandra Mining large-scale response networks reveals 'topmost activities' in Mycobacterium tuberculosis infection Sci. Rep. 2013 3 2302
114. K. Raman A. G. Bhat N. Chandra A systems perspective of host-pathogen interactions: predicting disease outcome in tuberculosis Mol. BioSyst. 2010 6 3 516 530
115. E. F. Egelund A. B. Barth C. A. Peloquin Population pharmacokinetics and its role in anti-tuberculosis drug development and optimization of treatment Curr. Pharm. Des. 2011 17 27 2889 2899
116. M. A. Lyons et al., A physiologically based pharmacokinetic model of rifampin in mice Antimicrob. Agents Chemother. 2013 57 4 1763 1771
117. B. Reisfeld et al., A physiologically based pharmacokinetic model for capreomycin Antimicrob. Agents Chemother. 2012 56 2 926 934
118. S. Goutelle et al., Mathematical modeling of pulmonary tuberculosis therapy: insights from a prototype model with rifampin J. Theor. Biol. 2011 282 1 80 92
119. S. Goutelle et al., Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs Antimicrob. Agents Chemother. 2009 53 7 2974 2981
120. N. R. Budha et al., A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria Tuberculosis 2009 89 5 378 385
121. Y. Lemmer et al., A Model of Isoniazid Treatment of Tuberculosis J. Theor. Biol. 2014 363 367 373
122. M. Lipsitch B. R. Levin The population dynamics of antimicrobial chemotherapy Antimicrob. Agents Chemother. 1997 41 2 363 373
123. A. K. Chavali et al., Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease BMC Syst. Biol. 2012 6 27
124. A. K. Chavali et al., A metabolic network approach for the identification and prioritization of antimicrobial drug targets Trends Microbiol. 2012 20 3 113 123
125. B. J. Schmidt J. A. Papin C. J. Musante Mechanistic systems modeling to guide drug discovery and development Drug Discovery Today 2013 18 3-4 116 127
126. G. L. Drusano et al., Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis PLoS One 2014 9 7 e101311
127. B. Prideaux et al., High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions Anal. Chem. 2011 83 6 2112 2118
128. B. Prideaux et al., Mass spectrometry imaging of levofloxacin distribution in TB-infected pulmonary lesions by MALDI-MSI and continuous liquid microjunction surface sampling Int. J. Mass Spectrom. 2015 377 699 708
129. G. J. Churchyard et al., Advances in immunotherapy for tuberculosis treatment Clin. Chest Med. 2009 30 4 769 782
130. G. A. Rook D. B. Lowrie R. Hernandez-Pando Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J. Infect. Dis. 2007 196 2 191 198
131. R. S. Wallis Reconsidering adjuvant immunotherapy for tuberculosis Clin. Infect. Dis. 2005 41 2 201 208
132. M. N. Ragheb et al., The mutation rate of mycobacterial repetitive unit loci in strains of M. tuberculosis from cynomolgus macaque infection BMC Genomics 2013 14 145